1590P - The investigate relationship between severe neutropenia and ABCB1and ABCG2 gene polymorphisms with esophageal cancer patients receiving docetaxel,...

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Oesophageal Cancer
Supportive measures
Supportive and Palliative Care
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Hisanaga Nomura
Citation Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388
Authors H. Nomura1, D. Tsuji2, K. Demachi1, S. Suzuki1, N. Mochizuki1, T. Yano3, H. Daiko4, S. Fujii5, T. Kojima6, K. Ito2, M. Yamaguchi1
  • 1Pharmacy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2Clinical Phrmacology & Genetics, University of Shizuoka, 4228002 - Shizuoka/JP
  • 3Gastroenterology, Endoscopy Division, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4Esophageal Surgery, National Cancer Center Hospital, 104-0045 - Chu-o/JP
  • 5Pathology, Exploratory Oncology Research And Clinical Trial Center, National Cancer Center, 277-8577 - Kashiwa/JP
  • 6Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP



The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is a newly developed chemotherapy for esophageal cancer (EC) patients (pts). Severe neutropenia is one of the major adverse events that necessitate chemotherapy dose reduction. This study aimed to investigate relationship between grade 3 and 4 neutropenia and genetic polymorphisms in EC pts received DCF.


EC pts who had undergone DCF chemotherapy at National Cancer Center Hospital East from August 2011 to December 2016 were enrolled in this study. Prophylactic administration of granulocyte-colony stimulating factor was not conducted for the all EC pts during the above chemotherapy. Seven polymorphisms in the genes encoding docetaxel-metabolizing enzymes and transporters were genotyped, and then relationship between these genotypes and the grade 3 and 4 neutropenia was then investigated. Risk factors that enable to predict grade 3 and 4 neutropenia after first cycle of chemotherapy were explored using multivariate logistic regression analysis.


A total of 170 pts treated with DCF were enrolled in this study period. The median age was 64 years, median body mass index was 22.0 (15.3 - 31.0), median serum hemoglobin level was 13.5 (8.7 - 17.1) g/dL, median prognostic nutritional index was 50.1 (36.7 - 68.7) and baseline absolute neutrophil count (ANC) was 4305 (1660 - 11020)/mm3. The proportion of pts with grade 3 and 4 neutropenia was 56 (32.9%) and 34 (21.2%), respectively. Multivariate logistic regression analysis adjusted for potential risk factors revealed ABCB1 3435C > T (p = 0.015), ABCG2 34G > A (p=0.044), age (60


We identified that genetic polymorphisms in ABCB1 3435 C > T and ABCG2 34 G > A was a significant predictor for grade 3 and 4 neutropenia of EC pts receiving DCF.

Clinical trial identification

Legal entity responsible for the study

National Cancer Center Hospital East




All authors have declared no conflicts of interest.